Navigation Links
NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting
Date:2/18/2011

to 85% of subjects which indicates that the VLP vaccine will be important in addressing future influenza pandemics.  Novavax VLPs are unique as they are made in a non-egg-based, recombinant manufacturing system that produces particles resembling the influenza virus but which renders them more immunogenic than simple recombinant vaccines."

Methods

This Phase II randomized, double-blind, placebo-controlled trial was conducted at a single study center in Mexico to evaluate the safety, tolerability, and immunogenicity of 3 dose levels (5mcg, 15mcg, and 45mcg HA) of the novel (H1N1) influenza VLP vaccine as compared with a placebo in healthy adults aged 18 to 64 years.  The study was conducted in two parts: Part A was to evaluate the safety and immunogenicity of the H1N1 influenza VLP vaccine over a dose range and to select a dose for an expanded safety evaluation in Part B. In Part A, 1,013 subjects were enrolled (760 active and 253 placebo). Based on an interim safety and immunogenicity analysis, an additional 3,547 (2,535 active and 1,012 placebo) subjects were enrolled in Part B of the study, a safety only study, and received 15mcg of VLP vaccine or placebo as a single injection on Day 1 using a second lot of H1N1 VLP vaccine.

Safety

In Part A, adverse events (AEs) were similar for the placebo group and for the active vaccine groups, except that dose-related local injection site reactions were reported more frequently in the active vaccine groups.  In Part B of the study, the incidence of AEs was consistent with that of Part A and was comparable between the VLP and placebo groups.  The results for the 15mcg vaccine in Part A and Part B of the study demonstrated that the different vaccine lots exhibited comparable safety profiles.  Across all subjects in Part A and Part B, the majority of AEs were of mild or moderate severity and resolved without sequelae and all serious AEs were considered defin
'/>"/>

SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NOVAVAX to Present H1N1 VLP Influenza Vaccine Clinical Data at 7th World Health Organization (WHO) Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials
2. NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial
3. NOVAVAX to Present at Lazard 7th Annual Healthcare Conference
4. NOVAVAX Reports Third Quarter 2010 Financial Results
5. Novavax to Report Third Quarter 2010 Financial Results on November 5, 2010
6. NOVAVAX to Present at BIO Investor Forum
7. NOVAVAX to Present at Stifel Nicolaus Conference
8. NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures
9. NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines
10. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2010
11. Novavaxs Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , September 23, 2014 ... has announced the addition of the  "Large ... to their offering.  ,     ... drug delivery market holds significant potential for ... vials and painful needles to the modern-day ...
(Date:9/23/2014)... SAN FRANCISCO , Sept. 23, 2014  SiteOne ... round of equity financing. Led by Sears Capital Management ... and Joe Zakrzewski , the $1.5 million financing ... inhibitor program for pain and to further develop its ... other pain indications. In conjunction with the ...
(Date:9/23/2014)... September 23, 2014 According ... by Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), ... Orthopedics) - Global Forecasts to 2019", published by ... forecast period of 2014 to 2019. The market ... at CAGR of 9.6% from 2014 to 2019. ...
Breaking Medicine Technology:Large Volume Wearable Injectors - 2nd Edition 2Large Volume Wearable Injectors - 2nd Edition 3Large Volume Wearable Injectors - 2nd Edition 4Large Volume Wearable Injectors - 2nd Edition 5SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 4
... Oct. 12, 2011 Reportlinker.com announces that ... in its catalogue: ... Region 2010-2014 ... the Peripheral Vascular Devices market in the ...
... (NYSE: BSX ) will webcast its conference call ... 2011 on Thursday, October 20, at 8:00 a.m. ET. ... becomes Boston Scientific,s Chief Executive Officer on October 17, and ... A live webcast of the conference call will be ...
Cached Medicine Technology:Peripheral Vascular Device Market in the APAC Region 2010-2014 2Boston Scientific To Webcast Conference Call Discussing Third Quarter 2011 Financial Results 2
(Date:9/23/2014)... (PRWEB) September 23, 2014 AttorneyOne.com, a ... all the latest information from the FDA on ... 5, that its Private Label Jalapeno Bagels are recalled ... stones. Publix Jalapeno Bagels were sold in ... department. , Taking into consideration the latest developments, ...
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- A test used to diagnose ... where certain lung infections are more common, a new analysis ... is through the use of what,s known as functional imaging. ... FDG-PET is used, according to the study authors. Cancerous ... parts of the lungs that don,t have cancer, according ...
(Date:9/23/2014)... Grinnell Mutual seeks submissions from the public ... Working Together Making It Better will provide grants ... positively impacting their communities. , “So many people ... a better places,” said Grinnell Mutual ... “Their leadership—as coaches, as volunteers, as mentors—help to ...
(Date:9/23/2014)... who are already obese as teenagers could grow up ... peers of normal weight. So says Petter Lundborg of ... Rooth of Linneas University and Lund University, all in ... United Kingdom and the United States, and the results ... , The researchers analyzed large-scale data of 145,193 Swedish-born ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 ... allergic rhinitis (AR) is highly fragmented, with ... SIT formulations available, under different regulatory restrictions, ... markets. Europe has the most developed market, ... and allergen immunotherapy tablets (AITs) all being ...
Breaking Medicine News(10 mins):Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:Grinnell Mutual Invites Submissions for Innovative, Collaborative Local Projects in Its Second Annual Working Together Making It Better Promotion 2Health News:Note to young men: Fat doesn't pay 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 4
... and community for decades, PHILADELPHIA, Nov. 11 ... leading health insurer, turns 70,years old. While health ... 1938, experts agree that access to affordable,quality health ... was a key,consideration when millions cast their vote ...
... Introducing ReBound(TM) the Revolution in Thermotherapy, ALAMEDA, ... and,ReGear Life Sciences announced today the introduction of ... to treat pain, muscle,spasms, and joint contractures using ... for providing state-of-the-art injury treatment systems,to the physical ...
... triglycerides throughout the body , , TUESDAY, Nov. 11 (HealthDay ... the risk of high blood pressure in women who ... of a new study by U.S. researchers who analyzed ... Study. , Lipoprotein particles carry cholesterol and triglycerides throughout ...
... walls as thick as that of a middle-aged person ... days are 13 going on 45, at least when ... presented Tuesday at the American Heart Association,s annual scientific ... representative of someone three decades older. , "These data ...
... NEW YORK, Nov. 11 Today, the ... the results of a,nationwide survey on the ... "Unfortunately, APIC failed to connect the dots,",says ... to Reduce Infection,Deaths (RID). "The new data ...
... 11 Pam Kreager, Director of,Clinical Quality ... Term,Care Group, Inc. (LTCG), has been elected ... (LTCIF). The Long Term Care International Forum,( ... is to promote,efficiency, effectiveness and high standards ...
Cached Medicine News:Health News:Independence Blue Cross Celebrates 70 Years Of Service In Southeastern Pennsylvania 2Health News:Independence Blue Cross Celebrates 70 Years Of Service In Southeastern Pennsylvania 3Health News:Independence Blue Cross Celebrates 70 Years Of Service In Southeastern Pennsylvania 4Health News:Independence Blue Cross Celebrates 70 Years Of Service In Southeastern Pennsylvania 5Health News:Game Ready(TM) and ReGear Life Sciences(TM) Bring Innovative New Heat Therapy to Market 2Health News:Game Ready(TM) and ReGear Life Sciences(TM) Bring Innovative New Heat Therapy to Market 3Health News:Lipoprotein Levels May Predict Women's Hypertension Risk 2Health News:Obese Kids Have Old Arteries 2Health News:Obese Kids Have Old Arteries 3Health News:APIC Covers Up Extent and Causes of Deadly C. diff 2Health News:Long Term Care International Forum names LTCG's Pam Kreager as President 2
The original battery-operated suction and irrigation system features a new ergonomic hand piece and superior performance characteristics that have increased the overall flow rate....
... of both worlds, the PeaceKeeper 20 ... latest addition to the Wet-Field comprehensive ... instruments for ophthalmic surgery. Combining highly ... and backflush functionality in a single ...
...
...
Medicine Products: